Tags

Type your tag names separated by a space and hit enter

Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso.
Vaccine. 2018 11 12; 36(47):7170-7178.V

Abstract

BACKGROUND

Burkina Faso was one of the first African nations to introduce pentavalent rotavirus vaccine (RV5, RotaTeq) into its national immunization program in October 2013. We describe the impact and effectiveness of rotavirus vaccine on acute gastroenteritis (AGE) hospitalizations among Burkinabe children.

METHODS

Sentinel hospital-based surveillance for AGE was conducted at four hospitals during December 2013 - February 2017. Demographic, clinical, and vaccination information was collected and stool specimens were tested by EIA. Trends in rotavirus AGE hospitalizations and changes in the proportion of AGE hospitalizations due to rotavirus were examined at two sentinel sites from January 2014 - December 2016. Unconditional logistic regression models using data from all 4 surveillance sites were used to calculate vaccine effectiveness (VE, defined as 1-odds ratio) by comparing the odds of vaccination among rotavirus AGE (cases) and non-rotavirus AGE (controls) patients, controlling for age, season, hospital site and socioeconomic factors.

RESULTS

The proportion of AGE hospitalizations that tested positive for rotavirus declined significantly among children <5 years of age, from 36% (154/422) in 2014 to 22% (71/323, 40% reduction, p < .01) in 2015 and 20% (61/298, 44% reduction, p < .01) in 2016. Among infants, the percentage of AGE admissions due to rotavirus fell significantly from 38% (94/250) in 2014 to 21% (32/153, 44% reduction, p < .01) in 2015 and 17% (26/149, 54% reduction, p < .01) in 2016. The adjusted VE for full 3-dose series of RV5 against rotavirus hospitalization was 58% (95% [CI], 10%, 81%) in children 6-11 months of age and 19% (-78%, 63%) in children ≥12 months.

CONCLUSION

Rotavirus hospitalizations declined after introduction of pentavalent rotavirus vaccine in children, particularly among infants. RV5 significantly protected against severe rotavirus gastroenteritis in infants, but effectiveness decreased in older children.

Authors+Show Affiliations

University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso; National Public Health Laboratory, Ouagadougou, Burkina Faso. Electronic address: ouindgueta@gmail.com.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Internal Medicine C, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel.Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso.National Immunization Program, Minister of Health, Ouagadougou, Burkina Faso.National Immunization Program, Minister of Health, Ouagadougou, Burkina Faso.National Immunization Program, Minister of Health, Ouagadougou, Burkina Faso.Centre hospitalier Régional de Gaoua, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso; Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso; Yalgado Ouédraogo University Hospital, Ouagadougou, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso; Yalgado Ouédraogo University Hospital, Ouagadougou, Burkina Faso.University Ouaga 1 Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso; Charles de Gaulle Pediatric University Hospital, Ouagadougou, Burkina Faso.World Health Organization, Burkina Faso Office, Ouagadougou, Burkina Faso.World Health Organization, IST/WA, Ouagadougou, Burkina Faso.World Health Organization, Regional Office for Africa, Brazzaville, Congo.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

29290478

Citation

Bonkoungou, Isidore Juste O., et al. "Impact and Effectiveness of Pentavalent Rotavirus Vaccine in Children <5 Years of Age in Burkina Faso." Vaccine, vol. 36, no. 47, 2018, pp. 7170-7178.
Bonkoungou IJO, Aliabadi N, Leshem E, et al. Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso. Vaccine. 2018;36(47):7170-7178.
Bonkoungou, I. J. O., Aliabadi, N., Leshem, E., Kam, M., Nezien, D., Drabo, M. K., Nikiema, M., Ouedraogo, B., Medah, I., Konaté, S., Ouédraogo-Traoré, R., Sangaré, L., Kam, L., Yé, D., Ouattara, M., Biey, J. N., Mwenda, J. M., Tate, J. E., & Parashar, U. D. (2018). Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso. Vaccine, 36(47), 7170-7178. https://doi.org/10.1016/j.vaccine.2017.12.056
Bonkoungou IJO, et al. Impact and Effectiveness of Pentavalent Rotavirus Vaccine in Children <5 Years of Age in Burkina Faso. Vaccine. 2018 11 12;36(47):7170-7178. PubMed PMID: 29290478.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso. AU - Bonkoungou,Isidore Juste O, AU - Aliabadi,Negar, AU - Leshem,Eyal, AU - Kam,Madibèlè, AU - Nezien,Désiré, AU - Drabo,Maxime K, AU - Nikiema,Moumouni, AU - Ouedraogo,Boureima, AU - Medah,Isaïe, AU - Konaté,Souleymane, AU - Ouédraogo-Traoré,Rasmata, AU - Sangaré,Lassana, AU - Kam,Ludovic, AU - Yé,Diarra, AU - Ouattara,Ma, AU - Biey,Joseph N, AU - Mwenda,Jason M, AU - Tate,Jacqueline E, AU - Parashar,Umesh D, Y1 - 2017/12/28/ PY - 2017/08/21/received PY - 2017/12/06/revised PY - 2017/12/18/accepted PY - 2018/1/2/pubmed PY - 2019/2/15/medline PY - 2018/1/2/entrez KW - Acute gastroenteritis KW - Burkina Faso KW - Hospitalization KW - Rotavirus KW - Vaccine effectiveness SP - 7170 EP - 7178 JF - Vaccine JO - Vaccine VL - 36 IS - 47 N2 - BACKGROUND: Burkina Faso was one of the first African nations to introduce pentavalent rotavirus vaccine (RV5, RotaTeq) into its national immunization program in October 2013. We describe the impact and effectiveness of rotavirus vaccine on acute gastroenteritis (AGE) hospitalizations among Burkinabe children. METHODS: Sentinel hospital-based surveillance for AGE was conducted at four hospitals during December 2013 - February 2017. Demographic, clinical, and vaccination information was collected and stool specimens were tested by EIA. Trends in rotavirus AGE hospitalizations and changes in the proportion of AGE hospitalizations due to rotavirus were examined at two sentinel sites from January 2014 - December 2016. Unconditional logistic regression models using data from all 4 surveillance sites were used to calculate vaccine effectiveness (VE, defined as 1-odds ratio) by comparing the odds of vaccination among rotavirus AGE (cases) and non-rotavirus AGE (controls) patients, controlling for age, season, hospital site and socioeconomic factors. RESULTS: The proportion of AGE hospitalizations that tested positive for rotavirus declined significantly among children <5 years of age, from 36% (154/422) in 2014 to 22% (71/323, 40% reduction, p < .01) in 2015 and 20% (61/298, 44% reduction, p < .01) in 2016. Among infants, the percentage of AGE admissions due to rotavirus fell significantly from 38% (94/250) in 2014 to 21% (32/153, 44% reduction, p < .01) in 2015 and 17% (26/149, 54% reduction, p < .01) in 2016. The adjusted VE for full 3-dose series of RV5 against rotavirus hospitalization was 58% (95% [CI], 10%, 81%) in children 6-11 months of age and 19% (-78%, 63%) in children ≥12 months. CONCLUSION: Rotavirus hospitalizations declined after introduction of pentavalent rotavirus vaccine in children, particularly among infants. RV5 significantly protected against severe rotavirus gastroenteritis in infants, but effectiveness decreased in older children. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/29290478/Impact_and_effectiveness_of_pentavalent_rotavirus_vaccine_in_children_<5_years_of_age_in_Burkina_Faso_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(17)31817-0 DB - PRIME DP - Unbound Medicine ER -